Related Experiment Video
Updated: Aug 9, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Epidemiology of insulin-using commercial motor vehicle drivers. Major variability of state licensing requirements in
I F Gower1, T J Songer, H Hylton
1Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA 15261.
Objective:
Licensing agencies in many areas, including the U.S., prohibit insulin-using individuals from driving CMVs or large trucks. This study examined the debate over the risks of licensing insulin-using individuals to drive CMVs as an occupation, and the variations in regulations of different states.
Research Design And Methods:
As part of an ongoing review of the regulations governing interstate commerce in the U.S., we surveyed all 50 states and Washington, D.C. to determine the regulations concerning intrastate driving. We received responses from 48 states and D.C., representing 95% of the U.S. population.
Results:
Only 9 states reported preventing insulin users from acquiring a CMV license, whereas 39 states and D.C. permitted licensing within state boundaries. Of the states allowing insulin users to drive, 26 placed special requirements on CMV licensing.
Conclusions:
The results indicate that, despite a standardized U.S. federal law for driving across states, enormous variability exists in the policies for driving within states, ranging from no restrictions to a complete ban on CMV driving for insulin users.
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Dosage Regimen: Individualization
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type I Diabetes III: Clinical Manifestations

